News – Page 506 – Endpoints News

Left behind at the Covid vaccine starting line, CureVac files suit against BioNTech over megablockbuster IP claims

3 years ago

'We strongly dissent': Women biotech execs pen letter to colleagues and politicians in Roe v. Wade aftermath

3 years ago

Hitching a quick ride on the M&A train, AstraZeneca wagers $100M cash on T cell engager

3 years ago

Seagen touts full PhII Tukysa data as it plots colorectal cancer expansion

3 years ago

WuXi Biologics inspection raises prospects for getting off US 'unverified list' — report

3 years ago

Pharma reacts to post-Roe; Drugmakers beef up cyber defense; Boehringer, Roche quietly axe drugs; and more

3 years ago

From Tampa to Munich, Amgen’s ‘Places’ campaign introduces its locations around the world

3 years ago

Lonza to invest $500M+ on fill-finish facility on its home turf

3 years ago

Biohaven takes migraine campaign to patients' Twitter feeds, months ahead of Pfizer takeover

3 years ago

US government more than doubles the supply of monkeypox vaccine

3 years ago

What’s been on influential oncologists' minds? Mostly ASCO, but also health equity, according to new Harris Poll ...

3 years ago

Novartis to decide on spinning off $25B generics arm Sandoz by year's end

3 years ago

Teva chief raids Vertex for his new global head of research and development

3 years ago

Small Massachusetts biotech tries to beat back the bears with $55M PIPE

3 years ago

With chance to take on Bristol Myers' $13B heart drug, Cytokinetics preps for pivotal studies with $450M debt raise

3 years ago

#BIO22: Managing a biotech in turbulent times. 'There's a perfect shitshow out there'

3 years ago

Endo adds to a pileup of bad news as lead drug flunks PhII study

3 years ago

Covid-19 roundup: Oxford Biomedica and AstraZeneca extend vaccine deal; FDA wants boosters for newer variants

3 years ago

Bayer's research and development teams settle into new, $140M Kendall Square digs

3 years ago

Provention's second shot at FDA approval for diabetes prevention drug hits new hurdle

3 years ago

Otsuka pays Akebia $55M to formally end vadadustat partnership, waving goodbye to the $1B deal

3 years ago

Taking aim at Xolair, Celldex offers a positive early readout for their rival drug — but researchers have a lot of ...

3 years ago

Swatting away a takeover attempt, Zymeworks keeps retooling staff; After Cygnal-ing her exit from Flagship, Pearl ...

3 years ago

Pharma industry spent a record $389M on US lobbying in 2021, but more is likely coming this year — report

3 years ago

First page Previous page 503 504 505506507 508 509 Next page Last page